drugset
drugset / Trial / NCT05553301

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301 ↗

Phase 1/2 Completed 560 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Timeline

Start
2022-10-03
Primary completion
2024-01-19
Completion
2024-01-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Flublok Quadrivalent Vaccine — Intramuscular
Comparator Fluzone High-Dose Quadrivalent Vaccine — Intramuscular
Subject MRT5407 Messenger RNA (mRNA) — Intramuscular
Comparator Quadrivalent Influenza Standard Dose Vaccine Vaccine — Intramuscular

Indications

No indication recorded.